Early treatment of refractory cardiogenic shock with percutaneous veno-arterial ECMO implanted in the cardiac catheterization laboratory.

l T adjustment for the GRACE (Global Registry of Acute Coronary Events) score at hospital discharge, and a trend toward a lower mortality rate persisted (HR = 0.52; 95%CI, 0.26-1.07; P = .075) (Figure). Thus, we conclude that, in routine clinical practice, it is not uncommon to encounter patients admitted for NSTEACS who have severe anemia (3 out of every 100), a comorbidity that will influence the treatment of the coronary event, and most patients are undertreated with respect to currently recommended drug therapy. The prognosis of these patients is frankly poor, with a mortality rate higher than 10% during the hospital stay and greater than 50% at 3 years. The interventional strategy has not been